Original language | English (US) |
---|---|
Pages (from-to) | 444-447 |
Number of pages | 4 |
Journal | Circulation |
Volume | 139 |
Issue number | 4 |
DOIs | |
State | Published - Jan 22 2019 |
Funding
Dr Shah is supported by grants from the National Institutes of Health (R01 HL140731, R01 HL120728, and R01 HL107577) and the American Heart Association (16SFRN28780016 and 15CVGPSD27260148) and by Actelion, Astra-Zeneca, Corvia, and Novartis; and has received consulting fees from Actelion, Amgen, AstraZeneca, Bayer, Boehringer-Ingelheim, Cardiora, Eisai, Ionis, Ironwood, Merck, Novartis, Pfizer, Sanofi, and United Therapeutics.
Keywords
- Editorials
- amyloidosis
- heart failure
- precision medicine
ASJC Scopus subject areas
- Cardiology and Cardiovascular Medicine
- Physiology (medical)